We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Association of plasma and CSF cytochrome P450, soluble epoxide hydrolase, and ethanolamide metabolism with Alzheimer's disease.
- Authors
Borkowski, Kamil; Pedersen, Theresa L.; Seyfried, Nicholas T.; Lah, James J.; Levey, Allan I.; Hales, Chadwick M.; Dammer, Eric B.; Blach, Colette; Louie, Gregory; Kaddurah-Daouk, Rima; Newman, John W.
- Abstract
Background: Alzheimer's disease, cardiovascular disease, and other cardiometabolic disorders may share inflammatory origins. Lipid mediators, including oxylipins, endocannabinoids, bile acids, and steroids, regulate inflammation, energy metabolism, and cell proliferation with well-established involvement in cardiometabolic diseases. However, their role in Alzheimer's disease is poorly understood. Here, we describe the analysis of plasma and cerebrospinal fluid lipid mediators in a case–control comparison of ~150 individuals with Alzheimer's disease and ~135 healthy controls, to investigate this knowledge gap. Methods: Lipid mediators were measured using targeted quantitative mass spectrometry. Data were analyzed using the analysis of covariates, adjusting for sex, age, and ethnicity. Partial least square discriminant analysis identified plasma and cerebrospinal fluid lipid mediator discriminates of Alzheimer's disease. Alzheimer's disease predictive models were constructed using machine learning combined with stepwise logistic regression. Results: In both plasma and cerebrospinal fluid, individuals with Alzheimer's disease had elevated cytochrome P450/soluble epoxide hydrolase pathway components and decreased fatty acid ethanolamides compared to healthy controls. Circulating metabolites of soluble epoxide hydrolase and ethanolamides provide Alzheimer's disease predictors with areas under receiver operator characteristic curves ranging from 0.82 to 0.92 for cerebrospinal fluid and plasma metabolites, respectively. Conclusions: Previous studies report Alzheimer's disease-associated soluble epoxide hydrolase upregulation in the brain and that endocannabinoid metabolism provides an adaptive response to neuroinflammation. This study supports the involvement of P450-dependent and endocannabinoid metabolism in Alzheimer's disease. The results further suggest that combined pharmacological intervention targeting both metabolic pathways may have therapeutic benefits for Alzheimer's disease.
- Subjects
EPOXIDE hydrolase; ALZHEIMER'S disease; CYTOCHROME P-450; CEREBROSPINAL fluid examination; CARDIOVASCULAR diseases; ENCEPHALITIS
- Publication
Alzheimer's Research & Therapy, 2021, Vol 13, Issue 1, p1
- ISSN
1758-9193
- Publication type
Article
- DOI
10.1186/s13195-021-00893-6